Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 23:17:1598245.
doi: 10.3389/fnagi.2025.1598245. eCollection 2025.

Tau and tauopathies across primate species: implications for modeling neurodegenerative disorders

Affiliations
Review

Tau and tauopathies across primate species: implications for modeling neurodegenerative disorders

Julia C Colwell et al. Front Aging Neurosci. .

Abstract

Tauopathies are neurodegenerative disorders characterized by the abnormal accumulation and aggregation of hyperphosphorylated tau protein. They can be primary or secondary depending on whether tau inclusions are the predominant pathology (e.g.: frontotemporal dementia related to tau) or are found with other proteinopathies (e.g.: Alzheimer's disease), respectively. Currently, there are no effective treatments to prevent or slow down progressive tau accumulation. Animal models play a critical role in the efforts to unravel the mechanisms leading to tauopathies and identifying therapeutic targets. Nonhuman primates (NHPs) present several advantages for the study of tauopathies, as they have complex neuroanatomy and behavior that resembles human traits, and their tau gene and protein are highly conserved. Moreover, aged NHPs, like humans, can present various tau inclusions in their brains, although whether NHPs can develop human-like tau-related neurodegenerative disorders is currently debated. The main goal of this review is to analyze available reports on tau pathologies and models of tauopathies in NHPs considering the complexity of the tau protein and associated tau pathologies. Here, we first summarize current available information on human and NHP tau under physiological conditions in order to highlight species differences and gaps in knowledge. We then analyze reports on tau pathologies in aged NHPs compared to human aging and tauopathy, followed by an evaluation of current and emerging NHP models of tauopathy. Lastly, we discuss the practical and ethical challenges of doing tauopathy research in NHPs, and how to best leverage it to ultimately find solutions for patients with these disorders.

Keywords: AT8; Alzheimer’s disease; aging; frontemporal dementia; neurofibrillary tangles; nonhuman primates; tau; tauopathies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Tau protein in human and nonhuman primate species. (A) Tau has four distinct regions: (1) the N-terminal projection domain (blue outline), (2) the proline-rich region (orange outline), (3) the microtubule binding domain (purple outline), and (4) the C-terminus (yellow outline). Colored boxes represent constitutively expressed exons; empty boxes are exons subject to alternative splicing that translate into (B) the six CNS isoforms of the tau protein. Expression of exons 4a, 6, and 8 is restricted to the human PNS and retina. (C) The longest CNS tau isoform in primates is the 2N4R tau. Black ticks in the protein region identifies amino acid (aa) variations in 2N4R tau in each nonhuman primate species compared to the human sequence. Common marmosets, squirrel monkeys, and gray mouse lemur tau has aa deletions, indicated by dashed black lines through the exons in which they occur. Gray mouse lemurs have an aa addition in exon 2, denoted by a solid black line through the exon. Created in https://BioRender.com.
Figure 2
Figure 2
Examples of AT8+ postmortem tau pathologies in human cases of Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), Pick’s disease (PiD), and corticobasal degeneration (CBD). (A) Pretangle (arrowhead) and mature NFT (arrow) in the cornu ammonis (AD). (B) Dystrophic neurites (arrowhead) in the entorhinal cortex (AD). (C) Neuritic plaque (arrow) in the insula (AD). (D) Globose NFT (arrow) in the putamen nucleus (PSP). (E) Pick bodies (arrow) in the cornu ammonis (PiD). (F) Oligodendroglial coiled bodies (arrowheads) in the putamen nucleus (PSP). (G) Thorn-shaped astrocyte (arrow) in the subpial medial temporal lobe (AD). (H) Tufted astrocyte (arrow) in the putamen (PSP). (I) Astrocytic plaque (arrow) in the caudate nucleus (CBD). Scale bar, 100 μm.
Figure 3
Figure 3
Approximate age in years (yrs.) of life milestones across female species from representative primate families. Chimpanzees reach sexual maturity between 8.5–14 yrs. of age and are on average 15 yrs. old when they first give birth (Walker et al., 2018); their fertility declines in their 30s and experience menopause at 45–50 yrs. old (Wood et al., 2023). In rhesus, first birth often occurs at age 4 (Pittet et al., 2017) and their fertility declines around age 17 (Lee et al., 2021); menopause was reported by 24–26 yrs. old (Walker, 1995). Common marmosets are considered primed adults between 2 and 8 yrs. of age, although they do not seem to undergo reproductive senescence (Abbott et al., 2003). Gray mouse lemurs reach sexual maturity around 0.5 yrs. (Hohenbrink et al., 2015) and, like common marmosets, do not seem to experience reproductive senescence. Their median lifespan is 5.5 yrs. (Martine and Aude, 2022) but can live up to 18 yrs. in captivity. Listed maximum lifespans in NHPs are estimated for captive animals. Mature tau pathologies, like NFTs, have been reported in extremely old animals nearing their respective species’ maximum lifespan, yet without behavioral or clinical correlates, it is difficult to assert whether tau pathology affects survivability. Created in https://BioRender.com.

Similar articles

  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • Fabricating mice and dementia: opening up relations in multi-species research.
    Davies G, Gorman R, Milne R. Davies G, et al. In: Jenkins N, Jack-Waugh A, Ritchie L, editors. Multi-Species Dementia Studies. Bristol (UK): Bristol University Press; 2025 Feb 25. Chapter 2. In: Jenkins N, Jack-Waugh A, Ritchie L, editors. Multi-Species Dementia Studies. Bristol (UK): Bristol University Press; 2025 Feb 25. Chapter 2. PMID: 40690569 Free Books & Documents. Review.
  • Short-Term Memory Impairment.
    Cascella M, Al Khalili Y. Cascella M, et al. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
  • Digital interventions in mental health: evidence syntheses and economic modelling.
    Gega L, Jankovic D, Saramago P, Marshall D, Dawson S, Brabyn S, Nikolaidis GF, Melton H, Churchill R, Bojke L. Gega L, et al. Health Technol Assess. 2022 Jan;26(1):1-182. doi: 10.3310/RCTI6942. Health Technol Assess. 2022. PMID: 35048909 Free PMC article.
  • Systemic Inflammatory Response Syndrome.
    Baddam S, Burns B. Baddam S, et al. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613449 Free Books & Documents.

References

    1. Abbott D. H., Barnett D. K., Colman R. J., Yamamoto M. E., Schultz-Darken N. J. (2003). Aspects of common marmoset basic biology and life history important for biomedical research. Comp. Med. 53, 339–350. doi: 10.1016/B978-0-12-811829-0.00001-7 - DOI - PubMed
    1. Alquezar C., Arya S., Kao A. W. (2020). Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front. Neurol. 11:595532. doi: 10.3389/fneur.2020.595532, PMID: - DOI - PMC - PubMed
    1. Amos L. A. (2004). Microtubule structure and its stabilisation. Org. Biomol. Chem. 2, 2153–2160. doi: 10.1039/b403634d, PMID: - DOI - PubMed
    1. Andreadis A. (2005). Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta 1739, 91–103. doi: 10.1016/j.bbadis.2004.08.010, PMID: - DOI - PubMed
    1. Andreadis A. (2013). Tau splicing and the intricacies of dementia. J. Cell. Physiol. 227, 1220–1225. doi: 10.1002/jcp.22842 - DOI - PMC - PubMed

LinkOut - more resources